Investigational Drug Information for Surufatinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Surufatinib?
Surufatinib is an investigational drug.
There have been 54 clinical trials for Surufatinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2015.
The most common disease conditions in clinical trials are Carcinoma, Neuroendocrine Tumors, and Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Sun Yat-sen University, and Fujian Cancer Hospital.
There are four US patents protecting this investigational drug and forty-six international patents.
Summary for Surufatinib
| US Patents | 4 |
| International Patents | 46 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2015-12-07) |
| Vendors | 41 |
Recent Clinical Trials for Surufatinib
| Title | Sponsor | Phase |
|---|---|---|
| Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC | Beijing Chest Hospital | Phase 2 |
| Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | Bai-Rong Xia | Phase 2 |
| Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | Sun Yat-sen University | Phase 2 |
Clinical Trial Summary for Surufatinib
Top disease conditions for Surufatinib
Top clinical trial sponsors for Surufatinib
US Patents for Surufatinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Surufatinib | See Plans and Pricing | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) | See Plans and Pricing |
| Surufatinib | See Plans and Pricing | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) | See Plans and Pricing |
| Surufatinib | See Plans and Pricing | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | Hutchison MediPharma Limited (Shanghai, CN) | See Plans and Pricing |
| Surufatinib | See Plans and Pricing | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | Hutchison Medipharma Limited (Shanghai, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Surufatinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Surufatinib | Argentina | AR119655 | 2038-07-25 | See Plans and Pricing |
| Surufatinib | Australia | AU2018433575 | 2038-07-25 | See Plans and Pricing |
| Surufatinib | Australia | AU2022203683 | 2038-07-25 | See Plans and Pricing |
| Surufatinib | Brazil | BR112021001148 | 2038-07-25 | See Plans and Pricing |
| Surufatinib | Canada | CA3153630 | 2038-07-25 | See Plans and Pricing |
| Surufatinib | China | CN112584875 | 2038-07-25 | See Plans and Pricing |
| Surufatinib | China | CN112867512 | 2038-07-25 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
